寻找下一个格列卫：针对急性髓系白血病的FLT3靶向激酶抑制剂疗法。
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
作者信息
Sawyers Charles L
机构信息
Department of Medicine, Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles 90095, USA.
出版信息
Cancer Cell. 2002 Jun;1(5):413-5. doi: 10.1016/s1535-6108(02)00080-6.
Abstract
Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.
摘要
FLT3受体酪氨酸激酶的激活突变发生在30%的急性髓系白血病患者中。小分子FLT3激酶抑制剂在临床前模型中显示出选择性抗肿瘤活性。临床研究正在进行中。
Zotero 插件